(NASDAQ: LGVN) Longeveron's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.15%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 65.97%.
Longeveron's earnings in 2026 is -$23,474,000.On average, 5 Wall Street analysts forecast LGVN's earnings for 2026 to be -$25,202,697, with the lowest LGVN earnings forecast at -$25,932,794, and the highest LGVN earnings forecast at -$24,102,769. On average, 5 Wall Street analysts forecast LGVN's earnings for 2027 to be -$16,259,805, with the lowest LGVN earnings forecast at -$18,121,712, and the highest LGVN earnings forecast at -$14,059,949.
In 2028, LGVN is forecast to generate -$2,926,765 in earnings, with the lowest earnings forecast at -$17,496,825 and the highest earnings forecast at $12,720,906.